Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ragweed Allergy - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Ragweed Allergy - Pipeline Review, H1 2015', provides an overview of the Ragweed Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ragweed Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ragweed Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ragweed Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ragweed Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ragweed Allergy Overview 6 Therapeutics Development 7 Pipeline Products for Ragweed Allergy - Overview 7 Pipeline Products for Ragweed Allergy - Comparative Analysis 8 Ragweed Allergy - Therapeutics under Development by Companies 9 Ragweed Allergy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Ragweed Allergy - Products under Development by Companies 14 Ragweed Allergy - Companies Involved in Therapeutics Development 15 Allergy Therapeutics plc 15 Anergis SA 16 Biomay AG 17 Circassia Pharmaceuticals plc 18 Immunomic Therapeutics, Inc. 19 Stallergenes S.A. 20 Ragweed Allergy - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 AllerR - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 BM-34 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Drug for Ragweed Pollen Allergy - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Multi-LAMP-Vax - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 PL-101 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Pollinex Ragweed - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ragweed hypoallergenic vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Ragweed-SPIRE - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Ragweed Allergy - Recent Pipeline Updates 37 Ragweed Allergy - Dormant Projects 39 Ragweed Allergy - Discontinued Products 40 Ragweed Allergy - Product Development Milestones 41 Featured News & Press Releases 41 Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR 41 Dec 08, 2014: Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study 41 Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting 42 Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine 43 Mar 07, 2012: Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 44 Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46
List of Tables Number of Products under Development for Ragweed Allergy, H1 2015 7 Number of Products under Development for Ragweed Allergy - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Comparative Analysis by Unknown Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Ragweed Allergy - Pipeline by Allergy Therapeutics plc, H1 2015 15 Ragweed Allergy - Pipeline by Anergis SA, H1 2015 16 Ragweed Allergy - Pipeline by Biomay AG, H1 2015 17 Ragweed Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015 18 Ragweed Allergy - Pipeline by Immunomic Therapeutics, Inc., H1 2015 19 Ragweed Allergy - Pipeline by Stallergenes S.A., H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Route of Administration, H1 2015 24 Number of Products by Stage and Molecule Type, H1 2015 26 Ragweed Allergy Therapeutics - Recent Pipeline Updates, H1 2015 37 Ragweed Allergy - Dormant Projects, H1 2015 39 Ragweed Allergy - Discontinued Products, H1 2015 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.